首页> 外文期刊>Drugs - Real World Outcomes >Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
【24h】

Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System

机译:伊维菌素大规模给药后的中枢和周围神经系统疾病:基于刚果民主共和国药物警戒系统的描述性研究

获取原文
       

摘要

IntroductionThe mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. ObjectivesThe objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC). MethodsThis is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009–2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12. ResultsA total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for “probable/possible Loa loa encephalopathy temporally related to mectizan?” (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6–3834.6; n =?23]. Post-treatment, 61% of PLERM cases had L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality. ConclusionPLERM may occur at even low peripheral blood concentrations of microfilaria.
机译:引言目前,控制盘尾丝虫病的主要方法是依维菌素的大量给药。但是,如果在盘尾丝虫病和疯牛病并存的地区使用,可能会导致严重的不良事件,包括死亡。目的本研究的目的是描述在刚果民主共和国(DRC)大量服用伊维菌素后发生的中枢和周围神经系统疾病。方法这是一项回顾性描述性研究,涉及对与伊维菌素大规模给药相关的不良事件的数据进行回顾。从世界卫生组织(WHO)全球个人病例安全报告(ICSR)数据库(VigiBase)中提取了在刚果民主共和国大规模施用伊维菌素后报告的严重不良事件的数据。审查涵盖了2009-2013年,重点是中枢和周围神经系统疾病。提取了相关的人口统计,临床和寄生虫学数据,包括年龄,性别,居住面积,不良事件和寄生虫密度。使用Stata 12分析描述性统计数据。结果在VigiBase中提供了与伊维菌素摄入量相关的52种ICSR,其中来自赤道省的51种(98.1%)。所有患者均患有中枢和周围神经系统疾病; 25名(48.1%)的心理状况改变了。其中,有23(92.0%)个符合“暂时与mectizan ?相关的Loa loa脑病”的标准(PLERM)。 PLERM患者中最常见的神经系统疾病是昏迷(74%),木僵(30%),头痛(22%)和步态异常(22%)。平均而言,外周血中每毫升(mf / ml)含有2149.1个微丝[[95%置信区间(CI)463.6–3834.6; n =?23]。治疗后,PLERM病例中有61%的血液中有L. loa mf / ml。一名患者的微丝虫病存在于脑脊液而非外周血中。我们发现恶性疟原虫共感染21.4%,死亡率4%。结论即使外周血微丝aria浓度较低,也可能发生PLERM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号